

# Hyemyung Seo

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7712218/hyemyung-seo-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47  
papers

2,040  
citations

23  
h-index

45  
g-index

48  
ext. papers

2,442  
ext. citations

7.4  
avg. IF

4.61  
L-index

#	Paper	IF	Citations
47	Spotting-based differentiation of functional dopaminergic progenitors from human pluripotent stem cells.. <i>Nature Protocols</i> , <b>2022</b> ,	18.8	3
46	Brain cells derived from Alzheimer's disease patients have multiple specific innate abnormalities in energy metabolism. <i>Molecular Psychiatry</i> , <b>2021</b> ,	15.1	16
45	Dysfunction of X-linked inhibitor of apoptosis protein (XIAP) triggers neuropathological processes via altered p53 activity in Huntington's disease. <i>Progress in Neurobiology</i> , <b>2021</b> , 204, 102110	10.9	0
44	Matrix Metalloproteinase-8 Inhibitor Ameliorates Inflammatory Responses and Behavioral Deficits in LRRK2 G2019S Parkinson's Disease Model Mice. <i>Biomolecules and Therapeutics</i> , <b>2021</b> , 29, 483-491	4.2	1
43	Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntington's disease mouse model. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , <b>2021</b> , 36, 856-868	5.6	1
42	Analysis of multi-omics data on the relationship between epigenetic changes and nervous system disorders caused by exposure to environmentally harmful substances.. <i>Environmental Toxicology</i> , <b>2021</b> ,	4.2	2
41	Iroquois Homeobox Protein 2 Identified as a Potential Biomarker for Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	1
40	Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 1926-1932	59.2	141
39	Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 904-920	15.9	55
38	HDAC Inhibition by Valproic Acid Induces Neuroprotection and Improvement of PD-like Behaviors in LRRK2 R1441G Transgenic Mice. <i>Experimental Neurobiology</i> , <b>2019</b> , 28, 504-515	4	17
37	Alpha-Synuclein Suppresses Retinoic Acid-Induced Neuronal Differentiation by Targeting the Glycogen Synthase Kinase-3/Catenin Signaling Pathway. <i>Molecular Neurobiology</i> , <b>2018</b> , 55, 1607-1619	6.2	12
36	Age-associated bimodal transcriptional drift reduces intergenic disparities in transcription. <i>Aging</i> , <b>2018</b> , 10, 789-807	5.6	5
35	Increase in anti-apoptotic molecules, nucleolin, and heat shock protein 70, against upregulated LRRK2 kinase activity. <i>Animal Cells and Systems</i> , <b>2018</b> , 22, 273-280	2.3	5
34	Cell-Penetrating Peptide-Patchy Deformable Polymeric Nanovehicles with Enhanced Cellular Uptake and Transdermal Delivery. <i>Biomacromolecules</i> , <b>2018</b> , 19, 2682-2690	6.9	24
33	Oxidized DJ-1 Levels in Urine Samples as a Putative Biomarker for Parkinson's Disease. <i>Parkinson's Disease</i> , <b>2018</b> , 2018, 1241757	2.6	10
32	Suppression of neuroinflammation by matrix metalloproteinase-8 inhibitor in aged normal and LRRK2 G2019S Parkinson's disease model mice challenged with lipopolysaccharide. <i>Biochemical and Biophysical Research Communications</i> , <b>2017</b> , 493, 879-886	3.4	14
31	Leucine-rich repeat kinase 2 exacerbates neuronal cytotoxicity through phosphorylation of histone deacetylase 3 and histone deacetylation. <i>Human Molecular Genetics</i> , <b>2017</b> , 26, 1-18	5.6	13

30	Age-associated chromatin relaxation is enhanced in Huntington's disease mice. <i>Aging</i> , <b>2017</b> , 9, 803-822	5.6	9
29	MiR-126 Regulates Growth Factor Activities and Vulnerability to Toxic Insult in Neurons. <i>Molecular Neurobiology</i> , <b>2016</b> , 53, 95-108	6.2	36
28	Elapachone increases phase II antioxidant enzyme expression via NQO1-AMPK/PI3K-Nrf2/ARE signaling in rat primary astrocytes. <i>Free Radical Biology and Medicine</i> , <b>2016</b> , 97, 168-178	7.8	37
27	Neuroanatomical Visualization of the Impaired Striatal Connectivity in Huntington's Disease Mouse Model. <i>Molecular Neurobiology</i> , <b>2016</b> , 53, 2276-86	6.2	7
26	G2385R and I2020T Mutations Increase LRRK2 GTPase Activity. <i>BioMed Research International</i> , <b>2016</b> , 2016, 7917128	3	23
25	Gene therapy by proteasome activator, PA28 $\beta$ improves motor coordination and proteasome function in Huntington's disease YAC128 mice. <i>Neuroscience</i> , <b>2016</b> , 324, 20-8	3.9	27
24	An early endosome regulator, Rab5b, is an LRRK2 kinase substrate. <i>Journal of Biochemistry</i> , <b>2015</b> , 157, 485-95	3.1	55
23	Reduction of Nfia gene expression and subsequent target genes by binge alcohol in the fetal brain. <i>Neuroscience Letters</i> , <b>2015</b> , 598, 73-8	3.3	9
22	Increased TRPC5 glutathionylation contributes to striatal neuron loss in Huntington's disease. <i>Brain</i> , <b>2015</b> , 138, 3030-47	11.2	63
21	LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase. <i>Nature Communications</i> , <b>2015</b> , 6, 8255	17.4	57
20	Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression. <i>Molecular Brain</i> , <b>2015</b> , 8, 54	4.5	38
19	Enhancement of BACE1 Activity by p25/Cdk5-Mediated Phosphorylation in Alzheimer's Disease. <i>PLoS ONE</i> , <b>2015</b> , 10, e0136950	3.7	29
18	miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 1712-21	5.6	94
17	JMJD2A attenuation affects cell cycle and tumorigenic inflammatory gene regulation in lipopolysaccharide stimulated neuroectodermal stem cells. <i>Experimental Cell Research</i> , <b>2014</b> , 328, 361-78	4.2	10
16	Prediction of miRNA-mRNA associations in Alzheimer's disease mice using network topology. <i>BMC Genomics</i> , <b>2014</b> , 15, 644	4.5	19
15	Systemic injection of LPS induces region-specific neuroinflammation and mitochondrial dysfunction in normal mouse brain. <i>Neurochemistry International</i> , <b>2014</b> , 69, 35-40	4.4	107
14	Baclofen, a GABAB receptor agonist, enhances ubiquitin-proteasome system functioning and neuronal survival in Huntington's disease model mice. <i>Biochemical and Biophysical Research Communications</i> , <b>2014</b> , 443, 706-11	3.4	19
13	Age-dependent effects of valproic acid in Alzheimer's disease (AD) mice are associated with nerve growth factor (NGF) regulation. <i>Neuroscience</i> , <b>2014</b> , 266, 255-65	3.9	26

12	Increased DJ-1 in urine exosome of Korean males with Parkinson's disease. <i>BioMed Research International</i> , <b>2014</b> , 2014, 704678	3	53
11	Identification of cancer-specific biomarkers by using microarray gene expression profiling. <i>Biochip Journal</i> , <b>2013</b> , 7, 57-62	4	8
10	Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 141ra90	17.5	381
9	The hAPP-YAC transgenic model has elevated UPS activity in the frontal cortex similar to Alzheimer's disease and Down's syndrome. <i>Journal of Neurochemistry</i> , <b>2010</b> , 114, 1819-26	6	7
8	Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. <i>Human Molecular Genetics</i> , <b>2008</b> , 17, 3144-53	5.6	32
7	Proteasome activator enhances survival of Huntington's disease neuronal model cells. <i>PLoS ONE</i> , <b>2007</b> , 2, e238	3.7	94
6	Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. <i>Experimental Neurology</i> , <b>2005</b> , 193, 469-80	5.7	92
5	Generalized brain and skin proteasome inhibition in Huntington's disease. <i>Annals of Neurology</i> , <b>2004</b> , 56, 319-28	9.4	151
4	A direct role of the homeodomain proteins Phox2a/2b in noradrenaline neurotransmitter identity determination. <i>Journal of Neurochemistry</i> , <b>2002</b> , 80, 905-16	6	38
3	Cortico-hippocampal APP and NGF levels are dynamically altered by cholinergic muscarinic antagonist or M1 agonist treatment in normal mice. <i>European Journal of Neuroscience</i> , <b>2002</b> , 15, 498-506 <sup>3,5</sup>	3.5	22
2	Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. <i>Trends in Neurosciences</i> , <b>2002</b> , 25, 79-84	13.3	153
1	Spatial memory testing decreases hippocampal amyloid precursor protein in young, but not aged, female rats. <i>Neuroscience Letters</i> , <b>2002</b> , 328, 50-4	3.3	24